Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Mirjacic Martinović, Katarina ^a   Babović, Nada ^a   Džodić, Radan ^a,b   Jurišić, Vladimir ^c   Matković, Suzana ^a   Konjević, Gordana ^a,b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c University of Kragujevac Medical Faculty   (Serbia)

Author keywords

CD25; IL 12 IL 18; Metastatic melanoma; NK cell cytotoxicity; NKG2D

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; NATURAL KILLER CELL RECEPTOR; PERFORIN; STAT4 PROTEIN;

ADULT; AGED; BIOSYNTHESIS; CASE CONTROL STUDY; CYTOTOXICITY; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; K-562 CELL LINE; MALE; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY;

ADULT; AGED; CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; K562 CELLS; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PERFORIN; RECEPTORS, NATURAL KILLER CELL; STAT4 TRANSCRIPTION FACTOR;

EID: 84928787890     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0479-z     Document Type: Article

References (41)

1. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013;132:536-44.
2. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15-22.
3. Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, et al. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front Immunol. 2014;5:87.
4. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013;2, e26097.
5. López-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S. NKG2D signaling in cancer immunosurveillance. Int J Cancer. 2015;136:1741-150.
6. de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol. 2014;92:237-44.
7. Kirkham CL, Carlyle JR. Complexity and diversity of the NKR-P1:Clr (Klrb1:Clec2) recognition systems. Front Immunol. 2014;5:214.
8. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112-7.
9. Rajalingam R. Overview of the killer cell immunoglobulin-like receptor system. Methods Mol Biol. 2012;882:391-414.
10. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-40.
11. Mirjačić Martinović KM, Babović NL, Džodić RR, Jurišić VB, Tanić NT, Konjević GM. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res. 2014;24:295-304.
12. Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther. 2013;13:1413-27.
13. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12:631-45.
14. Lasek W, Zagoz˙dz˙on R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63:419-35.
15. Srivastava S, Salim N, Robertson MJ. Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem. 2010;17:3353-7.
16. Wang Y, Fan KT, Li JM, Waller EK. The regulation and activity of interleukin-12. Front Biosci (Schol Ed). 2012;4:888-99.
17. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25:439-48.
18. Chaix J, Tessmer MS, Hoebe K, Fuséri N, Ryffel B, Dalod M, et al. Cutting edge: priming of NK cells by IL-18. J Immunol. 2008;181:1627-31.
19. Chijioke O, Münz C. Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front Immunol. 2013;4:365.
20. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. AJCC melanoma staging and classification. J Clin Oncol. 2009;2009(27):6199-206.
21. Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods. 1985;81:207-14.
22. Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedmah H, Fahey J, editors. Manual of clinical laboratory immunology. 3rd ed. Washington DC: American Society for Microbiology; 1986. p. 226-35.
23. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999;11:822-30.
24. Singh SM, Yanagawa H, Hanibuchi M, Miki T, Okamura H, Sone S. Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12. Int J Immunopharmacol. 2000;22:35-43.
25. Heidemann SC, Chavez V, Landers CJ, Kucharzik T, Prehn JL, Targan SR. TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets. J Clin Immunol. 2010;30:531-8.
26. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors. 2010;36:274-88.
27. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162:4511-20.
28. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 2012;72:2757-67.
29. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163-89.
30. Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami A, et al. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 2001;44:884-926.
31. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106:3483-97.
32. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307-13.
33. Lanier LL. DAP10-and DAP12-associated receptors in innate immunity. Immunol Rev. 2009;227:150-60.
34. da Silva RF, Petta CA, Derchain SF, Alici E, Guimarães F. Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia. Hum Immunol. 2014;75:777-84.
35. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol. 2010;184:902-11.
36. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol. 1998;161:3493-500.
37. Al Omar SY, Marshall E, Middleton D, Christmas SE. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology. 2011;133:94-104.
38. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142:847-56.
39. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012;209:2351-65.
40. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012;120:4751-60.
41. Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20:463-73.